Ocular Therapeutix (OCUL) Stock Price, Quote, News & History | Benzinga

Ocular Therapeutix Inc (OCUL) Stock Price, Quote, News & History

OCULNASDAQ

Trade with Public

Trade with Public

$9.08

-0.11-1.2%

Last update: Aug 10, 8:58 AM

Earnings: Q2 2026 Earnings were released on Mon Aug 3rd, before the market open

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$9.19

Close

-

Volume / Avg.

407.61K / 2.61M

Day Range

$9.04 - $9.31

52 Wk Range

6.23 - 16.44

Market Cap

$1.99B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

14.52%

Days to Cover

13.07

Recent Ocular Therapeutix, Inc. News

Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program

Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.

Vandana Singh

Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.

Avi Kapoor

Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.

Vandana Singh

GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday

Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19, TREE cut to $290.

Avi Kapoor

Gold Down 3%; Medtronic Earnings Top Views

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-238.24M

Investing Cash Flow (TTM)

-16.86M

Financing Cash Flow (TTM)

462.61M

Free Cash Flow (TTM)

-255.10M

Capital Expenditure (TTM)

-16.86M

Net Change in Cash (TTM)

207.51M

Analyst Trends and Forecast

1

Apr

2

May

3

Jun

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.50B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

37.78

PB Ratio (TTM)

3.88

Earnings Yield % (TTM)

-15.23%

Earnings Yield % (FWD)

-16.27%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.37

Company Debt

Total Debt

$72.80M

LT Debt

$72.80M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$598.64M

Debt to Equity

0.15

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$9.19

Close

-

Volume / Avg.

407.61K / 2.61M

Day Range

$9.04 - $9.31

52 Wk Range

6.23 - 16.44

Market Cap

$1.99B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

14.52%

Days to Cover

13.07

About

Sector

Health Care

Industry

Pharmaceuticals

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of e...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Ocular Therapeutix (OCUL) stock?

A

You can purchase shares of Ocular Therapeutix (NASDAQ:OCUL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Ocular Therapeutix (OCUL) competitors?

A

Other companies in Ocular Therapeutix’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Ocular Therapeutix (OCUL) stock?

A

Ocular Therapeutix has a consensus price target of $22.73.

Q

What is the current price for Ocular Therapeutix (OCUL)?

A

The stock price for Ocular Therapeutix (NASDAQ: OCUL) is $9.08 last updated August 10, 2026 at 8:58 AM EDT.

Q

Does Ocular Therapeutix (OCUL) pay a dividend?

A

There are no upcoming dividends for Ocular Therapeutix.

Q

When is Ocular Therapeutix (NASDAQ:OCUL) reporting earnings?

A

Ocular Therapeutix does not have any upcoming earnings scheduled.

Q

Is Ocular Therapeutix (OCUL) going to split?

A

There is no upcoming split for Ocular Therapeutix.

Q

What sector and industry does Ocular Therapeutix (OCUL) operate in?

A

Ocular Therapeutix is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.